Market Cap
$554.1M
DCTH
DELCATH SYSTEMS, INC.
$15.16 ▼ -1.62%
Prev close $15.41Market cap$554.1M
ConsensusStrong Buy
12-mo target$24.00 (+58.3%)
▲ Bullish
Analyst conviction 9/10
Insider Buying Cluster (2 insiders)High Impact Filing (8/10)17 New Institutional Positions6 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on DCTH right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$130.6M
Inst. Activity
17 buys / 6 sells
Insider Activity
$150.3K buy / $0.00 sell
Insider Net $
$150.3K
Social Sentiment
50° Neutral
SEC Reports
7
Price chart 30d -8.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 6, 2026 earnings_calendar
DCTH Q2 2026 Earnings Scheduled — 2026-08-06
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
2,706,802 shares ($34.1M)
Jun 30, 2026 Inst.
Jun 11, 2026 SEC ExodusPoint Capital Management, LP — DOUBLED
359,884 shares ($4.5M)
In Q3 2025, three institutional buyers (State Street, UBS, RenTech) added $1.0M in DCTH positions, while four sellers (F
INST-CLUSTER — Impact 4/10
Jun 9, 2026 Event
May 14, 2026 SEC Hepzato Kit
WARNING: PERI-PROCEDURAL COMPLICATIONS, MYELOSUPPRESSION Severe peri-procedural complications includ
Delcath Systems filed an 8-K reporting that stockholders approved an amendment to the 2020 Omnibus Equity Incentive Plan
8-K — Impact 3/10
May 13, 2026 Insider
CZEREPAK ELIZABETH was granted 22,500 shares
Director
May 13, 2026 Insider
SALAMON STEVEN A J was granted 22,500 shares
Director
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 6, 2026 | BTIG | MAINTAIN | Buy | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% |
Price targets
Where 5 covering analysts think DCTH trades over the next 12 months.
$24.00 +58.3% upside Strong Buy
Current$15.16 Low$21.00 Median$22.00 High$32.00 5 analysts
$21.00$32.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 3 bullish, 0 bearish, 1 mixed, 3 neutral · avg impact 5.0/10.
MIXEDINST-CLUSTER4/10
In Q3 2025, three institutional buyers (State Street, UBS, RenTech) added $1.0M in DCTH positions, w
Jun 11, 2026
NEUTRAL8-K3/10
Delcath Systems filed an 8-K reporting that stockholders approved an amendment to the 2020 Omnibus E
May 14, 2026
NEUTRAL8-K5/10
Delcath Systems reported Q1 2026 revenue of $25.0M (+26% YoY), beating the $23.4M consensus, but pos
May 7, 2026
NEUTRALDEFA14A3/10
Delcath Systems, Inc. filed definitive additional proxy materials (DEFA14A) related to a shareholder
Apr 2, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 10, 2026
Clinical Trial
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Phase Phase 3 — COMPLETED
Aug 6, 2026
earnings_calendar
DCTH Q2 2026 Earnings Scheduled — 2026-08-06
Jun 9, 2026
FDA
Hepzato Kit
WARNING: PERI-PROCEDURAL COMPLICATIONS, MYELOSUPPRESSION Severe peri-procedural complications including hemorrhage, hepatocellular injury, and thrombo
Jun 8, 2026
short_volume
Short Volume: DCTH — 66.8% short (0.4M / 0.7M)
Short: 441,075 | Exempt: 989 | TRF Vol: 660,212 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
ftd
FTD: DCTH — 89,780 shares ($1.0M) failed to deliver
Settlement: 20260529, Price: $10.95, FTD Value: $983,091, DELCATH SYS INC
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.07 | $-0.13–$-0.01 | -450.0% | +66.3% | 0↑ 3↓ | $0.0B | 4 |
| Next Q | $-0.12 | $-0.18–$-0.04 | -140.0% | +57.5% | 0↑ 3↓ | $0.0B | 4 |
| Current FY | $-0.14 | $-0.22–$-0.01 | -268.8% | +77.7% | 0↑ 5↓ | $0.1B | 4 |
| Next FY | $0.04 | $0.01–$0.12 | 133.3% | +108.8% | 0↑ 4↓ | $0.1B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.070 | — |
| 7d ago | $-0.207 | +0.137 |
| 30d ago | $-0.207 | +0.137 |
| 60d ago | $-0.216 | +0.146 |
| 90d ago | $-0.216 | +0.146 |
Institutional ownership
Which big funds own DCTH (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $130.6M total value (10,377,373 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, GEODE. Net buying activity: 17 institutions added/increased vs 6 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 2,706,802 | $34.1M | 26.1% | ADD +51.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,221,247 | $15.4M | 11.8% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 733,115 | $9.2M | 7.1% | — |
| STATE STREET CORP | 679,280 | $8.6M | 6.5% | — |
| MILLENNIUM MANAGEMENT LLC | 566,371 | $7.1M | 5.5% | DOUBLED +138.6% |
| MORGAN STANLEY | 407,983 | $5.1M | 3.9% | — |
| ExodusPoint Capital Management, LP | 359,884 | $4.5M | 3.5% | DOUBLED +900.6% |
| NORTHERN TRUST CORP | 252,108 | $3.2M | 2.4% | — |
| GOLDMAN SACHS GROUP INC | 250,312 | $3.2M | 2.4% | DOUBLED +116.0% |
| MARSHALL WACE, LLP | 218,963 | $2.8M | 2.1% | DOUBLED +687.2% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 1,784,466 | 2,706,802 | +51.7% | $34.1M |
| ExodusPoint Capital Management, LP | DOUBLED | 35,968 | 359,884 | +900.6% | $4.5M |
| Nuveen, LLC | ADD | 103,774 | 181,595 | +75.0% | $2.3M |
| Man Group plc | ADD | 102,214 | 128,495 | +25.7% | $1.6M |
| BARCLAYS PLC | DOUBLED | 37,849 | 107,950 | +185.2% | $1.4M |
| Russell Investments Group, Ltd. | DOUBLED | 2,604 | 67,658 | +2498.2% | $851.8K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 13,018 | 57,654 | +342.9% | $725.9K |
| UBS Group AG | TRIM | 69,139 | 41,714 | -39.7% | $525.2K |
| SEI INVESTMENTS CO | TRIM | 44,058 | 31,369 | -28.8% | $394.9K |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | 12,158 | 30,054 | +147.2% | $378.4K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 7 transactions. Net $150.3K — $150.3K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 13, 2026 | CZEREPAK ELIZABETH | Director | AWARD | 22,500 | — | — |
| May 13, 2026 | SALAMON STEVEN A J | Director | AWARD | 22,500 | — | — |
| May 13, 2026 | Aharon Gil | Director | AWARD | 22,500 | — | — |
| May 13, 2026 | Martell Bridget A | Director | AWARD | 22,500 | — | — |
| May 13, 2026 | Sylvester John Richard | Director | AWARD | 22,500 | — | — |
| Mar 6, 2026 | Pennell Sandra | Chief Financial Officer | BUY | 5,533 | $9.04 | $50.0K |
| Mar 2, 2026 | MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | BUY | 11,200 | $8.96 | $100.3K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for DCTH.
Shares short
2,311,774
Settlement Sep 15, 2026
Change vs prior
+3.1%
Semi-monthly cycle
Days to cover
6.9
At avg daily volume
Of shares outstanding
≈6.7%
Estimate — not % of float
All DCTH filing & press-release reports (7)
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 14, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 2, 2026
- CLUSTER reportMar 6, 2026
- INST-CLUSTER reportFeb 28, 2026
- 8-K reportFeb 26, 2026